Project
Interferon-γ Release Assay (IGRA) Negativity Rates after TB-Treatment in HIV-infected Individuals
Automatically Closed · 2012 until 2013
Hoffmann Matthias, Ruhwald Morten, Hasse Barbara, Fenner Lukas, Schmid Patrick, Vernazza Pietro
Type
Range
Units
Status
Start Date
End Date
Financing
Partner
Brief description/objective
Background:
Interferon-γ Release assays (IGRA) have partly replaced conventional tuberculin skin tests (TST) in the recent years due to their higher specificity and standardised test procedures including a positive / negative control. Nevertheless it is currently unknown if IGRA reverse to negative results and in what time after successful TB-treatment in HIV-infected persons.
Study Aims:
The aim of the study is to evaluate the rate of positive / negative / indeterminate IGRA test results and absolute Mycobacterium tuberculosis-specific cytokine / chemokine secretion (IGRA-specific and purified protein derivate (PPD) –specific) titres in association with the time since successful tuberculosis (TB) -treatment as an indicator of the IGRA reversion rate over time, taking into account possible confounders, in particular CD4 recovery rate and TB re-exposure risk.
Study Design:
Cohort study analysing the effect of time since TB-treatment on IGRA / PPD negativity rates in all HIV-infected patients enrolled in the SHCS with previous treatment for active TB.